| C41 | No association between prenatal PrEP exposure and adverse growth outcomes among Kenyan infants: a prospective study | E-poster | PrEP and pregnant women |
| C41 | Navigating PrEP use and pregnancy: perspectives among adolescent girls and young women (AGYW) in Tshwane, South Africa | E-poster | PrEP and pregnant women |
| C41 | CAP016 PrEP in pregnancy - a phase 2b open-label randomised control safety study of daily oral TDF/FTC when used as pre-exposure prophylaxis for HIV prevention in pregnant and lactating women | E-poster | PrEP and pregnant women |
| C27 | Global adoption of guidelines on and use of oral pre-exposure prophylaxis (PrEP): current situation and future projections | On-demand oral abstract session | PrEP |
| C27 | Early predictors of seroconversion among enrolees in a PrEP program in Brazil, Mexico and Peru ' the IMPREP Demonstration study | On-demand oral abstract session | PrEP |
| C27 | Comparing adherence to HIV Pre-Exposure Prophylaxis (PrEP) among new, male PrEP users initiating F/TAF vs. F/TDF | On-demand oral abstract session | PrEP |
| C27 | Variation in preferences for long-acting injectable PrEP among US men who have sex with men: a latent class analysis | On-demand oral abstract session | PrEP |
| C27 | Estimated long-acting PrEP effectiveness in the HPTN 084 cohort using a model-based HIV incidence in the absence of PrEP | On-demand oral abstract session | PrEP |
| C27 | SARS CoV-2 seroprevalence among HIV-negative participants using tenofovir/emtricitabine- based PrEP in 2020 ' a sub-study of PREVENIR-ANRS and SAPRIS-Sero | On-demand oral abstract session | PrEP |
| C27 | Real-world utilization of F/TDF and F/TAF for HIV Pre-exposure Prophylaxis during the COVID-19 pandemic in the US, December 2019 ' June 2020 | On-demand oral abstract session | PrEP |